SCHEMBL8459972

SCHEMBL8459972

CC(C)(C)c1ccc(C(=O)/C=C/c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.78
SMN1; SMN2 Q16637 3/20 0.78
TP53 P04637 1/20 0.78
CYP3A4 P08684 1/20 0.78
ALOX15 P16050 1/20 0.78
MAPK1 P28482 1/20 0.78
BLM P54132 1/20 0.78
CASP7 P55210 1/20 0.78
HSD17B10 Q99714 1/20 0.78
TDP1 Q9NUW8 1/20 0.78
XDH P47989 1/20 0.63
CYP1A2 P05177 1/20 0.62
SRD5A2 P31213 1/20 0.59
CYP1B1 Q16678 6/20 0.57
CYP1A1 P04798 5/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
MAOB P27338 2/20 0.56
P4HB P07237 1/20 0.55
F3 P13726 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8459973 1.00 MAPT (0.78) MAPTSMN1; SMN2TP53CYP3A4ALOX15
SCHEMBL16051996 0.93 CYP1A2 (0.70) MAPTSMN1; SMN2TP53CYP3A4ALOX15
SCHEMBL16051995 0.93 CYP1A2 (0.70) MAPTSMN1; SMN2TP53CYP3A4ALOX15
SCHEMBL10070198 0.89 MAPT (0.68) MAPTSMN1; SMN2TP53CYP3A4ALOX15
SCHEMBL16052183 0.89 CYP1B1 (0.71) MAPTSMN1; SMN2TP53CYP3A4ALOX15
SCHEMBL23082321 0.89 CYP1A2 (0.64) MAPTSMN1; SMN2TP53CYP3A4ALOX15
SCHEMBL28481451 0.89 MAPT (0.68) MAPTSMN1; SMN2TP53CYP3A4ALOX15
SCHEMBL10070189 0.89 CYP1B1 (0.71) MAPTSMN1; SMN2TP53CYP3A4ALOX15
SCHEMBL23082314 0.89 CYP1A2 (0.64) MAPTSMN1; SMN2TP53CYP3A4ALOX15
SCHEMBL8458037 0.88 SRD5A2 (0.69) MAPTSMN1; SMN2TP53CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118445349-A Implementation method for quickly constructing operator visualization model by web terminal 北京中科锦智数字技术有限公司 2024-08-06 CN claimed
US-20260144857-A1 SHIGELLA MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION AND FUSION PROTEINS THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2026-05-28 US disclosed
US-20260049215-A1 ASPHALT COMPOSITION AND PRODUCTION METHOD THEREFOR RESONAC CORPORATION (JP) 2026-02-19 US disclosed
EP-4644488-A1 ASPHALT COMPOSITION AND PRODUCTION METHOD THEREFOR Resonac Corporation (JP) 2025-11-05 EP disclosed
EP-4360617-B1 FORMULATION COMPRISING ESTER QUATS BASED ON TRIALKANOLAMINES EVONIK OPERATIONS GMBH (DE) 2025-07-02 EP disclosed
CN-113552768-B Photosensitive coloring composition, color filter and image display device 爱天思株式会社 2025-06-17 CN disclosed
EP-4563663-A1 ASPHALT EMULSION COMPOSITION AND METHOD FOR PRODUCING SAME Resonac Corporation (JP) 2025-06-04 EP disclosed
CN-119677814-A Asphalt composition and method for producing same 株式会社力森诺科 2025-03-21 CN disclosed
CN-119604583-A Asphalt emulsion composition and method for producing same 株式会社力森诺科 2025-03-11 CN disclosed
CN-119372924-A Preparation method of particle decoration electrostatic spinning anti-corrosion coating with corrosion early warning and self-repairing functions 中国海洋大学 2025-01-28 CN disclosed
WO-2022172645-A1 COMPOUND IN WHICH POLYGLYCEROL, FATTY ACID, AND DICARBOXYLIC ACID HAVE BEEN ESTERIFIED 太陽化学株式会社 2022-08-18 WO disclosed
CN-110003126-B Preparation method of ultraviolet absorbent Tinuvin 928 威海金威化学工业有限责任公司 2022-07-22 CN disclosed
US-20220133846-A1 NOVEL ANTIMICROBIAL COMPOUND AND USES THEREOF FRAUNHOFER USA INC. (US) 2022-05-05 US disclosed
EP-3991794-A1 EXTERNAL PREPARATION FOR SKIN Kao Corporation (JP) 2022-05-04 EP disclosed
WO-2022085432-A1 SOLID SHAMPOO 花王株式会社 2022-04-28 WO disclosed
EP-3957659-A1 FUNCTIONALIZED POLYMERS Evonik Operations GmbH (DE) 2022-02-23 EP disclosed
WO-1999048529-A1 RETINOID-GLITAZONE COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-09-30 WO disclosed
EP-0808159-A1 USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) WARNER-LAMBERT COMPANY (US) 1997-11-26 EP disclosed
WO-1996024344-A1 USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) WARNER-LAMBERT COMPANY (US) 1996-08-15 WO disclosed
US-5489611-A ADMINISTERING A RETINOID COMPOUND WARNER-LAMBERT COMPANY (US) 1996-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144857-A1 SHIGELLA MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION AND FUSION PROTEINS THEREOF HLA-DRB1, SPOP, STXBP1 MAPT 1642/4885SMN1; SMN2 805/4885TP53 957/4885
US-20260049215-A1 ASPHALT COMPOSITION AND PRODUCTION METHOD THEREFOR LCAT, CETP, SOAT1 MAPT 19/4885SMN1; SMN2 2222/4885TP53 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.